IgG4-related disease in patients with newly diagnosed idiopathic retroperitoneal fibrosis: a population-based Danish study

2019 ◽  
Vol 48 (4) ◽  
pp. 320-325 ◽  
Author(s):  
N Lomborg ◽  
M Jakobsen ◽  
CS Bode ◽  
P Junker
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Population Based ◽  
Newly Diagnosed ◽  
Idiopathic Retroperitoneal Fibrosis ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Danish Study

Is it time to consider IgG4-related disease in idiopathic retroperitoneal fibrosis?

2015 ◽  
Vol 10 (3) ◽  
pp. 222-224
Author(s):  
Luke Teo ◽  
Daniel Jenkin ◽  
Shahir Hamdulay ◽  
Rajesh Kavia
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Idiopathic Retroperitoneal Fibrosis ◽  
Related Disease ◽  
Igg4 Related Disease

IgG4-Related Disease and Retroperitoneal Fibrosis

2015 ◽  
Author(s):  
John H. Stone
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Clinical Manifestations ◽  
Organ System ◽  
Idiopathic Retroperitoneal Fibrosis ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Mikulicz Disease ◽  
Histopathologic Findings ◽  
Chronic Periaortitis

IgG4-related disease (IgG4-RD) has been observed to affect almost every organ system, with consistent histopathologic findings across systems. IgG4-RD can mimic malignant, infectious, and inflammatory disorders; accordingly, consideration of the histopathologic features of tissue biopsies and rigorous clinicopathologic correlations are essential to avoid misdiagnosis. Since the early 2000s, IgG4-RD has increasingly been recognized as a cause of what was previously referred to as “idiopathic” retroperitoneal fibrosis (RPF), and this IgG4-related RPF is now considered to comprise an important subset of IgG4-RD. This review includes an overview of IgG4-RD and discusses the pathology, pathophysiology, and clinical manifestations of IgG4. IgG4-related RPF is also discussed in this review, with topics including IgG4-related RPF versus RPF of other causes, the differences between RPF and other subsets of IgG4-RD, and treatment of both IgG4-RD and IgG4-related RPF. Figures show the histopathology features of IgG4-RD, immunostaining of tissue for IgG4, IgG4-related RPF and chronic periaortitis, “Mikulicz disease”, IgG4-RD of the lung, IgG4-related renal disease, and type 1 (IgG4-related) pancreatitis. The table lists conditions known previously by other names that often fall within the spectrum of IgG4-RD. This review contains 7 highly rendered figures, 1 table, and 66 references.

Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease

2017 ◽  
Vol 12 (3) ◽  
pp. 287-299 ◽  
Author(s):  
Giovanni Maria Rossi ◽  
Rossana Rocco ◽  
Eugenia Accorsi Buttini ◽  
Chiara Marvisi ◽  
Augusto Vaglio
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Idiopathic Retroperitoneal Fibrosis ◽  
Related Disease ◽  
Igg4 Related Disease

scholarly journals A case of giant retroperitoneal lymphangioma and IgG4-positive fibrosis: Causality or coincidence?

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110169
Author(s):  
Kim Rouven Liedtke ◽  
Christoph Käding ◽  
Paula Döring ◽  
Sander Bekeschus ◽  
Anne Susann Glitsch
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Inflammatory Diseases ◽  
Histological Change ◽  
Iliac Vessel ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Cystic Tumors ◽  
Retroperitoneal Cyst ◽  
Retroperitoneal Lymphangioma ◽  
Severe Fibrosis

Several chronic inflammatory diseases have been found to be a subtype of IgG4-related disease, all of which have a typical clinical and histological change, which is based in particular on an overexpression of IgG4 and subsequent fibrosis. At least a part of the retroperitoneal fibrosis, which was originally classified as idiopathic, seems to be assigned to IgG4-related disease. Lymphangiomas are benign, cystic tumors that rarely occur in adults. However, there is no firm association with IgG4-related disease described in the literature to date. This report is about a patient suffering from acute renal failure due to a giant retroperitoneal cyst. Surgical resection remains incomplete in the iliac vessel area due to severe fibrosis and histology revealed features of both lymphangioma and IgG4+ fibrosis. The case description is followed by a brief overview of IgG4-related disease and a consideration of whether lymphangiomas might be assigned to this topic.

scholarly journals Erdheim-Chester Disease: The Importance of Information Integration

2017 ◽  
Vol 10 (2) ◽  
pp. 613-619 ◽  
Author(s):  
Anna Nikonova ◽  
Khashayar Esfahani ◽  
Guillaume Chausse ◽  
Stephan Probst ◽  
Tina Petrogiannis-Haliotis ◽  
...  
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
High Dose ◽  
Related Disease ◽  
Igg4 Related Disease ◽  
Erdheim Chester Disease ◽  
History Of ◽  
Erdheim Chester ◽  
Chester Disease

Background: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis disorder that utilizes the RAS-RAF-MEK-ERK pathway. It has a highly variable clinical presentation, where virtually any organ can be involved, thus having the potential of posing a great diagnostic challenge. Over half of the reported cases have the BRAF V600E mutation and have shown a remarkable response to vemurafenib. Case Presentation: We describe herein a patient with a history of stroke-like symptoms and retroperitoneal fibrosis that on initial pathology raised the possibility of IgG4-related disease. However, the patient was refractory to high-dose steroids and progressed further, developing an epicardial soft tissue mass and recurrent neurological symptoms. Integration of the above findings with new information at another hospital about a radiological history of symmetrical lower extremities long bone lesions raised the differential diagnosis of ECD. Molecular analysis of formalin-fixed paraffin-embedded tissue of both of the patient’s retroperitoneal biopsies (the second one of which had shown a small focus of foamy histiocytes, CD68+/CD1a–) was positive for BRAF mutation, confirming the diagnosis of ECD. The patient demonstrated a dramatic and sustained metabolic response to vemurafenib on follow-up positron emission tomography scans. Conclusion: This case highlights the need for developing a high index of suspicion for presentations of retroperitoneal fibrosis that could represent IgG4-related disease but fail to respond to steroids. When unusual multisystem involvement occurs, one should consider a diagnosis of a rare histiocytosis. Vemurafenib appears to be an effective treatment for even advanced cases of both ECD and Langerhans histiocytosis bearing the BRAF V600E mutation.

scholarly journals Retroperitoneal Fibrosis Diagnosed as IgG4-related Disease after 35 Years

2019 ◽  
Vol 58 (4) ◽  
pp. 609-613 ◽  
Author(s):  
Satoshi Konno ◽  
Yoshihiro Matsuno ◽  
Shingo Ichimiya ◽  
Masaharu Nishimura ◽  
Yoshikazu Kawakami
Keyword(s):  
Retroperitoneal Fibrosis ◽  
Related Disease ◽  
Igg4 Related Disease
Sign in / Sign up

Export Citation Format

Share Document